The 2nd International Congress on Clinical Trials on Cannabis (CT-Cann 2023) is dedicated to inform participants of the latest evidence and concepts regarding cannabinoid therapy, aid prescribers.
The 2nd International Congress on Clinical Trials on Cannabis (CT-Cann 2023) covers topics such as:
- Pharamacokinetics and pharmacodynamics of cannabinoids
- How can we predict the response to cannabinoid treatment?
- Phytocannabinoid study – strains, chemovars, entourage and molecules
- New and emerging designs for cannabis clinical trials
- Clinical cannabinoid therapy across medical specialties such as Pain, Gastroenterology, Palliative Care, Psychiatry and Neurology
- How to interpret clinical, observational and epidemiological studies: findings, interpretations, applicability
- Clinical Registries from around the globe – what can we learn?
- Cannabinoid trial best conduct including GCP and site training
- Regulatory, licensing, and legal considerations – effects on clinical availability and industry development
- National and international guidelines
- Assessing safety and adverse events of cannabinoid medications
- Translating Current Evidence to Clinical Practice
- Where is the industry heading? A discussion with leaders in the field
The 2nd International Congress on Clinical Trials on Cannabis (CT-Cann 2023) brings together:
- Medical professionals
- Clinical Trial specialists
- Researchers
- General Practitioners
- Trialists
- Clinicians
- Medical professionals
- Methodologists
- The European Medical Agency
- Industry professionals The European Monitoring Centre for Drugs and Drug Addiction
- National cannabis agencies
